Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
October 1, 2025Open Access

Role and Indications for Device Therapies in Heart Failure: Condensed Summary

View Full Paper
Ask AI
Bookmark
Share

Authors

EOEileen O’MearaBMBlandine Mondésert

Discussion

Loading...

Member takes

Overview

Observational analysis highlights device therapy benefits for heart failure, indicating improved outcomes and risks.

Key Points

  • Device therapy remains crucial in managing heart failure, improving prognosis and preventing sudden cardiac death.
  • Cardiac resynchronization therapy notably aids patients with left bundle branch block, seen in 15–25% of heart failure cases.
  • Left ventricular remodeling affects heart failure outcomes, with therapies addressing dyssynchrony and cardiac output.
  • Right bundle branch block can also contribute to adverse remodeling, highlighting the need for comprehensive management.

Cite This Study

O’Meara et al. (2025) studied this question.

synapsesocial.com/papers/68dd91c7fe798ba2fc49830ehttps://doi.org/10.58931/cct.2025.127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Device treatment of heart failure2022 · 1 citations
  2. 2Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy in the Treatment of Heart Failure with Reduced Ejection Fraction2017 · 2 citations
  3. 3Contemporary management of heart failure patients with reduced ejection fraction: the role of implantable devices and catheter ablation2021 · 4 citations
  4. 4Electrical therapies in heart failure: Evolving technologies and indications2023 · 1 citations
  5. 5Cardiac Resynchronization Therapy for Heart Failure Management2004 · 5 citations